Ironwood Pharmaceuticals (IRWD) Panoramica del titolo
Ironwood Pharmaceuticals, Inc. è una società di biotecnologie che si concentra sullo sviluppo e la commercializzazione di terapie per malattie gastrointestinali (GI) e rare negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
IRWD Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Ironwood Pharmaceuticals, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$3.54 |
| Massimo di 52 settimane | US$5.78 |
| Minimo di 52 settimane | US$0.66 |
| Beta | 0.24 |
| Variazione di 1 mese | -9.69% |
| Variazione a 3 mesi | 16.45% |
| Variazione di 1 anno | 425.69% |
| Variazione a 3 anni | -66.73% |
| Variazione a 5 anni | -73.00% |
| Variazione dall'IPO | -69.61% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.
Aggiornamento della narrazione • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.Seeking Alpha • May 22
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Summary Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact. IRWD's revenue structure, based on profit-sharing with AbbVie for LINZESS, results in lumpy earnings and a compressed multiple. Read the full article on Seeking AlphaRecent updates
Aggiornamento della narrazione • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.Aggiornamento della narrazione • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.Seeking Alpha • May 22
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Summary Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact. IRWD's revenue structure, based on profit-sharing with AbbVie for LINZESS, results in lumpy earnings and a compressed multiple. Read the full article on Seeking AlphaArticolo di analisi • May 11
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...Aggiornamento della narrazione • May 01
IRWD: Earnings Outlook And Trial Updates Will Limit Future Share Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margins, and future P/E, while keeping their fair value estimate broadly unchanged at $3.70. What's in the News Ironwood plans to present data from the LANDMARK survey at the 2026 Digestive Disease Week meeting in Chicago, highlighting healthcare professional views on the burden of total parenteral nutrition for short bowel syndrome and preferred attributes for new therapies that reduce dependence on parenteral support (company announcement).Aggiornamento della narrazione • Apr 17
IRWD: Extended Revenue Guidance And Margin Assumptions Will Restrain Future Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, reflecting small tweaks to inputs such as discount rate, revenue growth assumptions, profit margin outlook and the future P/E multiple, while keeping their overall fair value estimate steady at $3.70. What's in the News Ironwood Pharmaceuticals reiterated its earnings guidance for 2026, stating that total revenue is expected to be in the range of $450 million to $475 million.Aggiornamento della narrazione • Apr 02
IRWD: Multi Year Revenue Guidance And Margin Assumptions Will Shape Outlook
Analysts have raised their price target on Ironwood Pharmaceuticals by $3, reflecting updated assumptions around fair value, a lower discount rate, higher projected revenue growth, a materially stronger profit margin outlook, and a reduced future P/E multiple. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in the range of $450 million to $475 million (company guidance).Aggiornamento della narrazione • Mar 19
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Analysts have modestly adjusted their price target on Ironwood Pharmaceuticals, now reflecting a $10.00 fair value that aligns with updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in a range of $450 million to $475 million.Aggiornamento della narrazione • Mar 05
IRWD: Index Inclusion And Reinforced Guidance Will Support Future Cash Flows
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $8.00 to $10.00, citing updated assumptions for revenue growth, profit margins, and future P/E expectations built into their models. What's in the News Ironwood Pharmaceuticals reiterated its 2026 earnings guidance, with total revenue expected in a range of $450 million to $475 million.Aggiornamento della narrazione • Feb 19
IRWD: Medicare Pricing Clarity Will Support Future Cash Flows And Optionality
Analysts have raised their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing clearer visibility on future Linzess pricing after the Centers for Medicare and Medicaid Services set a negotiated $136 Medicare price for a 30 day supply. They view this as supportive of the company as it reviews alternatives.
Aggiornamento della narrazione • Feb 05
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Ironwood Pharmaceuticals' analyst price target has moved higher, with the fair value estimate shifting from about US$2.50 to roughly US$4.85. Analysts cite updated revenue growth, profit margin and future P/E assumptions, along with recent Medicare pricing clarity for Linzess, as key drivers of their revised view.Aggiornamento della narrazione • Jan 22
IRWD: Medicare Pricing Clarity Will Support Future Earnings And Deal Optionality
Narrative Update Overview Analysts have raised their price target for Ironwood Pharmaceuticals to US$3.80 from US$1.70, citing clearer visibility on future Linzess Medicare pricing following the recent Inflation Reduction Act negotiation outcomes. Analyst Commentary Bullish analysts are highlighting the recent Medicare pricing outcome for Linzess as an important input into their updated view on Ironwood Pharmaceuticals.Aggiornamento della narrazione • Jan 07
IRWD: Medicare Price Certainty Will Support Stronger Earnings And Optionality
Analysts have lifted their 12 month fair value estimate for Ironwood Pharmaceuticals from $3.80 to $8.00, citing clearer Medicare pricing for Linzess and what they view as a stronger setup as the company reviews potential alternatives. Analyst Commentary Recent research has focused on how clearer Medicare pricing for Linzess could affect Ironwood Pharmaceuticals' valuation and options review.Articolo di analisi • Jan 06
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 32% gain in the last...Aggiornamento della narrazione • Dec 13
IRWD: Medicare Pricing Clarity Will Support More Predictable Earnings And Balanced Outlook
Analysts have lifted their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing improved visibility on Linzess Medicare pricing that supports higher long term profitability. This, they say, justifies a lower discount rate, a more stable revenue outlook, and a richer fair value assessment.Aggiornamento della narrazione • Nov 28
IRWD: Future Share Price Could Weaken Amid Upcoming Medicare Price Cuts
Analysts have increased their price target for Ironwood Pharmaceuticals to $3.80 from $1.70. They cite greater clarity on future Medicare pricing and strategic opportunities following recent policy announcements.Aggiornamento della narrazione • Nov 13
IRWD: Future Expectations May Not Justify Recent Share Price Levels
Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.Articolo di analisi • Nov 12
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders will have a reason to smile today, with the analysts making...Articolo di analisi • Nov 06
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Aggiornamento della narrazione • Oct 29
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Analysts have lowered their price target for Ironwood Pharmaceuticals from $0.95 to $0.95, citing reduced revenue growth expectations. This has been offset by improved profit margins and a lower discount rate.Articolo di analisi • Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Articolo di analisi • Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders are no doubt pleased to see that the share price has...Articolo di analisi • Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...Articolo di analisi • Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 1.6x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...
Nuova narrazione • Sep 17
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.Articolo di analisi • Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) recently...Articolo di analisi • Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...Seeking Alpha • Jun 20
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support. Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months. Read the full article on Seeking AlphaArticolo di analisi • Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 28% gain in the last...Rendimenti per gli azionisti
| IRWD | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -4.1% | 1.3% | 1.4% |
| 1Y | 425.7% | 31.4% | 25.7% |
Ritorno vs Industria: IRWD ha superato il US Biotechs che ha restituito 31.4 % nell'ultimo anno.
Rendimento vs Mercato: IRWD ha superato il mercato US che ha restituito 25.7 % nell'ultimo anno.
Volatilità dei prezzi
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di IRWD è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di IRWD è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1998 | 100 | Tom McCourt | ironwoodpharma.com |
Ironwood Pharmaceuticals, Inc. è una società di biotecnologie che si concentra sullo sviluppo e la commercializzazione di terapie per malattie gastrointestinali e rare negli Stati Uniti e a livello internazionale. Commercializza linaclotide, un agonista della guanilato ciclasi di tipo C (GC-C) per il trattamento di adulti affetti da sindrome dell'intestino irritabile con costipazione o da costipazione cronica idiopatica, nonché per pazienti pediatrici affetti da costipazione funzionale con i nomi LINZESS e CONSTELLA. L'azienda sta inoltre sviluppando IW-3300, un agonista del GC-C per il trattamento di condizioni di dolore viscerale, tra cui la cistite interstiziale/sindrome del dolore alla vescica e l'endometriosi; e Apraglutide, un analogo peptidico sintetico a lunga durata d'azione del peptide glucagone-simile-2 per i pazienti affetti da sindrome dell'intestino corto che dipendono dal supporto parenterale, nonché per la malattia acuta del trapianto contro l'ospite.
Ironwood Pharmaceuticals, Inc. Riepilogo dei fondamenti
| IRWD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$582.73m |
| Utili (TTM) | US$102.18m |
| Ricavi(TTM) | US$361.51m |
5.7x
Rapporto P/E1.6x
Rapporto P/SIRWD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| IRWD Conto economico (TTM) | |
|---|---|
| Ricavi | US$361.51m |
| Costo del fatturato | US$89.64m |
| Profitto lordo | US$271.87m |
| Altre spese | US$169.69m |
| Utili | US$102.18m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.62 |
| Margine lordo | 75.20% |
| Margine di profitto netto | 28.26% |
| Rapporto debito/patrimonio netto | -269.3% |
Come si è comportato IRWD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/22 06:52 |
| Prezzo dell'azione a fine giornata | 2026/06/18 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ironwood Pharmaceuticals, Inc. è coperta da 25 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |